c-Myc Oncoprotein: A Dual Pathogenic Role in Neoplasia and Cardiovascular Diseases?  by Napoli, Claudio et al.
c-Myc Oncoprotein: A Dual Pathogenic Role in Neoplasia and
Cardiovascular Diseases?
Claudio Napoli *,y, Lilach O. Lerman z, Filomena de Nigris *,y and Vincenzo Sica x
*Department of Medicine, University of California at San Diego, San Diego, CA, USA; yDepartment of Medicine,
University of Naples, Italy; zDepartment of Internal Medicine, Division of Hypertension, Mayo Clinic and
Foundation, Rochester, MN, USA; xDivision of Clinical Pathology, Second University of Naples, Italy
Abstract
A growing body of evidence indicates that c-Myc can
play a pivotal role both in neoplasia and cardiovascular
diseases. Indeed, alterations of the basal machinery of
the cell and perturbations of c-Myc–dependent signal-
ing network are involved in the pathogenesis of certain
cardiovascular disorders. Down-regulation of c-Myc
induced by intervention with antioxidants or by anti-
sense technologymay protect the integrity of the arterial
wall as well as neoplastic tissues. Further intervention
studies are necessary to investigate the effects of
tissue-specific block of c-Myc overexpression in the
development of cardiovascular diseases.
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Introduction
A great deal of work has focused on how oncogenes regulate
cell cycle during normal development and in cancer, yet their
roles in regulating cell growth have been largely unexplored
[1]. Recent studies in several experimental models have
demonstrated that homologues of some oncogenes regulate
cell growth and suggested that certain effects of oncogenes
on cell cycle may be a result of growth promotion [1]. These
studies have also suggested how growth and cell cycle
progression may be coupled.
The transcriptional regulatory proteins encoded by the c-
Myc proto-oncogene family have been linked to multiple
aspects of eukaryotic cell functions including cell cycle
progression, differentiation, neoplasia, and apoptosis [2-8].
c -Myc is characterized by the presence of basic-helix–
loop–helix (HLH) leucine zipper motif and is a transcriptional
regulator involved in carcinogenesis through its role in growth
control, cell cycle progression, and stimulation of the G1-S
transition. Examples of both positive and negative regulation
involving E-box and promoter elements have been reported.
In both cases, c-Myc is thought to induce changes in
transcription initiation. The HLH and zipper motif participate
in protein dimerization, a prerequisite for DNA binding. The
complete mechanism is still not well understood and c-Myc
can also control cell proliferation, survival, and transformation
regulating negatively p27 cyclin-dependent kinase inhibitor
in smooth muscle cells, breast cancer, and leukemia cells
[9 ]. In general, c-Myc regulates mammalian body size by
controlling cell number but not cell size [10]. Biological
evidence suggests the hypothesis that cancer and athero-
sclerosis and/or vasculoproliferative or other cardiovascular
diseases may share pathologic mechanisms, emphasizing
the need to perform studies investigating the involvement of
somatic mutations in these pathologic conditions.
c-Myc in Vascular Proliferative Disorders
Vasculoproliferative disorders and neointimal formation
occur during several pathophysiologic conditions. Together
with c-myb, c-Myc has been reported to be essential for
vascular smooth muscle cell (VSMC) proliferation [11]. For
example, restenosis following arterial injury consists mainly
of vascular cellular proliferation, which can ultimately lead
to arterial occlusion [12]. In addition, cell migration, matrix
deposition, and vascular remodeling are involved in
restenosis after arterial injury [13]. Following balloon injury,
c-Myc stimulates mitogenesis of quiescent VSMCs, and
tissue-selective expression of dominant -negative proteins
for c-Myc in combination with c-Myb blocks VSMC
proliferation in rat as well as human transfected VSMCs,
inducing apoptosis [14]. In another experimental setting,
molecular and histologic data demonstrate that c-Myc
mRNA was increased with a maximum at 4 hours after
surgical treatment [15]. A recent model of vascular
stenosis utilizes surgical injury for induction and develop-
ment of stenosis in the rat common carotid artery, which
mimics the injury occurring during implantation of arterial
grafts, endarterectomy, or organ transplantation [16].
Histologic and histochemical analysis of carotid sections
showed that morphologic changes, which occurred 30 days
after surgical injury in the arterial wall, were associated with
c-Myc overexpression. A number of data suggest that
angiotensin II–dependent activation of the proto-oncogene
c-Myc participates in the proliferative response of VSMCs
of rats with spontaneous hypertension (SHR) [17,18].
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Compared to normotensive Wistar–Kyoto rats, untreated
SHR exhibited increased percentage of cells expressing c-
Myc (P<0.05) and cyclin A (P<0.001) [17]. In quinapril -
treated SHR compared with untreated SHR, there was
decreased expression of c-Myc (P<0.005) and cyclin A
(P<0.001). Thus, an enhanced expression of c-Myc may
be involved in the increased proliferation seen in VSMCs
from SHR. Quinapril administration normalizes proliferation
in the VSMCs of SHR, possibly by inhibiting the
expression of the oncoprotein c-Myc and its effects on
the cell cycle. It was also demonstrated that ANG II
receptors, c-Myc, and c-Jun in myocytes are overex-
pressed after myocardial infarction and ventricular remod-
eling [19]. However, nitric oxide– induced apoptosis was
associated with c-Myc and CPP32 caspase activation [20]
and the cytotoxic effect of sodium nitroprusside on cancer
cells involves the suppression of c-Myc and c-Myb proto-
oncogene expression [21].
c-Myc antisense oligomers reduces neointimal formation
after arterial injury in pigs [22] as well as a phosphor-
othioated oligonucleotides in rat carotid arteries [23]. More-
over, local delivery of c-Myc neutrally charged antisense
oligonucleotides with transport catheter inhibits myointimal
hyperplasia and positively affects vascular remodeling in the
rabbit balloon- injury model [24]. These interventional
approaches require further investigation.
Autologous saphenous vein is one of the conduits of
choice for the bypass of arterial occlusive disease in either
the peripheral or coronary arterial circulation. This technique
is limited by high primary graft failure rates (approaching
20% in the first year for peripheral arterial disease and 50%
at 10 years for coronary artery bypass grafting), which is
often consequent to intimal hyperplasia. A role for c-Myc in
this process is suggested by its overexpression in vein graft
intimal hyperplasia [25], and may be mediated by the c-Myc
oncoprotein binding elongation 2 factor (E2F) that is
involved in the basal machinery of the cell. Interestingly,
the PREVENT trial describes a novel, relatively safe and
effective means of ex vivo transfection of harvested vein
grafts with an E2F decoy oligonucleotide, resulting in 70% to
74% decreases in the level of proliferating cell nuclear
antigen (PCNA) and c-Myc mRNA expression within the
vessel ( reviewed in Ref. [26] ). This translated into a
statistically significant reduction in failure of primary grafts
when these were subsequently used to bypass peripheral
arterial occlusions in a high- risk human patient population.
Finally, local delivery of mithramycin (a cell cycle
inhibitor ) restores vascular reactivity and inhibits neointimal
formation in injured arteries and vascular grafts [27]. These
studies indicated that perivascular implantation of drug-
loaded matrices led to 50% reduction of neointimal
formation and reduced the c-Myc expression and VSMC
proliferation in comparison to control implants. Moreover,
local perivascular mithramycin treatment limits the func-
tional alterations caused by the grafting of venous segments
in high-pressure arterial environment and potently inhibits
vascular stenosis secondary to grafting or angioplasty
injury.
c-Myc and Atherogenesis
Accumulationof lipidsandproliferationofVSMCsare themain
histologic features of atherosclerotic plaque formation. The
most prominent classical theory concerning the pathophysio-
logic mechanisms of atherosclerotic plaque formation is the
‘‘inflammatory response to injury’’ hypothesis, which
describes VSMC proliferation as an inflammation- fibroproli-
ferative reaction to different insults to the artery wall [28].
However, alterations at the DNA level may contribute
significantly to the development of the disease, and form the
basis for the ‘‘monoclonal’’ hypothesis of atherosclerosis
[29,30]. According to this hypothesis, atherosclerosis could
begin as a mutation or viral infection, transforming a single,
isolated VSMC into the progenitor of a proliferative clone, as
seen in carcinogenesis. Such a phenomenonmay involve the
enhanced expression of c-Myc demonstrated in human
VSMCs cultured from aortic plaques [31] and in carotid
atherosclerotic lesions [32]. Transforming genes and c-Myc
overexpression were also found in coronary VSMCs when
plaque DNA was transfected into fibroblast and the trans-
formed cells were injected into nude mouse [33]. The
mechanism by which c-Myc is activated is not well known
butoxidativestimuliactivatec-Myc( itsdimerizationwithMax)
E2F and AP-1, both in vitro and in vivo [34 ]. Indeed, c-Myc–
dependent signaling was found activated in early coronary
lesionsofWatanabeHeritableHyperlipidemic rabbits [34]and
in early coronary lipidotic accumulation in coronary vascular
wall of hypercholesterolemic pigs [35]. Abnormal expression
and dysfunction of this apoptosis- regulated gene may either
attenuate or accelerate vascular cell apoptosis and affect the
integrity and stability of plaques [34-36]. More important,
antioxidants downregulated c-Myc overexpression [34,35] in
a similar fashion to that observed in tumor cells [37].
In addition, estrogen and progesterone may also affect
VSMC gene expression of growth regulatory molecules such
as platelet -derived growth factor (PDGF), interleukin-1 ( IL-
1), interleukin-6 ( IL-6) and proto-oncogene c-Myc. In a
recent study, VSMCs were exposed to estrone sulfate (E1-
S) and medroxyprogesterone acetate (MPA) to induce
differentiation [38]. E1-S inhibited the expression of PDGF-
A chain, IL-1, IL-6, and c-Myc mRNA, whereas MPA had no
effect. Inhibition by E1-S was not affected by treatment
combined with MPA. These findings suggest that estrogen
but not progesterone modulates growth regulatory molecules
and c-Myc gene expression in VSMC. Thus, estrogen may
interfere with signals in the arterial wall through inhibition of
growth regulatory factors and this could affect vascular
diseases and atherogenesis. However, the c-Myc proto-
oncogene is an estrogen target gene in hormone-responsive
breast cancer, and hormonal progression of breast cancer
can be elicited by its enhanced expression through c-Myc
gene amplification and enhanced mRNA stability [39],
suggesting that its modulation by estrogen may depend on
other coexisting factors.
c-Myc in Cardiac Hypertrophy
Cellular oncogenes like c-Myc may participate in both the
normal developmental cell proliferation as well as in pressure
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overload or angiotensin II– induced cardiac hypertrophy [40-
42]. Recently, c-Myc overexpression was also reported to
correlate with left ventricular hypertrophy and dysfunction in
patients with chronic aortic regurgitation [43]. The expres-
sion of c-Myc was induced when the myocardial hypertrophy
was moderate. Nevertheless, when the myocardial hyper-
trophy was severe, cardiac myocytes failed to express the c-
Myc [44]. Similarly, the expression of c-Myc during
pressure-overloaded hypertrophy of the rat heart was
transient [40]. Several growth factors interacting with c-
Myc [38] influence cardiac hypertrophy, but cytokines do not
seem to play a mayor role in subsequent heart failure [45].
Furthermore, c-Myc, c- fos, and c-Jun, have been reported
to be implicated in the pathogenesis of myocardial remodel-
ing [40-42]. More recently, to determine the effects of de
novo c-Myc activity in adult postmitotic myocardium in vivo,
a novel transgenic model was investigated in which c-Myc is
expressed and inducibly activated specifically in cardiac
myocytes [46]. Activation of c-Myc in adult myocardium was
sufficient to reproduce the characteristic changes in myocyte
size, protein synthesis, and cardiac-specific gene expres-
sion seen in cardiac hypertrophy. However, despite the
increased cardiac mass, left ventricular function remained
normal. Hence, future studies will be needed to define the
role of c-Myc in cardiac hypertrophy and remodeling.
c-Myc in Cerebrovascular Ischemia and Reperfusion
Various stimuli also seem to activate c-Myc in the
cerebrovascular system. For example, reactive oxygen
species implicated in several pathologies act by activating
several transcription pathways, such as NFB as well as c-
Myc. During reperfusion injury after focal cerebral ischemia
in mice, reactive oxygen species regulate the activity of
NFB and c-Myc [47]. These factors were found increased
in ischemic zone and colocalized in apoptotic neuron.
Furthermore, overexpression of copper /zinc superoxide
dismutase in transgenic mice prevented activation of NFB,
B, blocked the expression of c-Myc, and reduced the
ischemic damage, suggesting a role for this pathway in
cerebrovascular reperfusion injury [47].
c-Myc and Neoplasia
The quantity of c-Myc is normally carefully controlled, and its
actions to induce and repress genes are modulated by
interactions with other regulatory proteins [2-8,48]. It is well
known that the c-Myc proto-oncogene plays a central role in
proliferation and malignant transformation of both human
and animal cells, and its amplification and/or overexpression
have been reported in most types of human malignancy
[7,8,49]. c -Myc regulation of growth affects both cellular size
and tissue differentiation, and this gene participates in most
aspects of cellular function, including replication, growth,
metabolism, differentiation, and apoptosis. The recent
availability of DNA chip microarray screen leads to the
identification of genes differentially involved in c-Myc and n-
Myc oncogenesis in human tumors [50]. c -Myc disrupts
genetic control in the early G1 phase of the cell cycle, and its
coexpression with Bcl -2 antagonizes the effects of the p53
tumor suppressor gene p53 on G1 arrest and apoptosis
[7,8,48,49,51]. c -Myc integrates the cell cycle machinery
with cell adhesion, cellular metabolism, and the apoptotic
pathways [7,8,49,51,52], and deregulation of its expression
is a common feature of multiple cancers [7,8 ], especially
many breast cancers [53]. Interestingly, there is c-Myc
overexpression in breast cancer and also in adjacent non-
neoplastic tissue [54]. This suggests an important causal
role of c-Myc–dependent downstream effects in breast
cancer. Furthermore, in melanoma, major histocompatibility
complex (MHC, HLA in humans) class I antigen expression
is suppressed by overexpression of the c-Myc proto-
oncogene and HLA-B locus, which is mainly affected by c-
Myc, is downmodulated at the level of initiation of tran-
scription [55]. Downregulation of MHC class I expression is a
mechanism by which tumor cells escape from T cell–
mediated lysis and these alterations have severe conse-
quences for the recognition of these tumor cells by the
immune system of the organism. HLA-B core promoter is
repressed by wild- type p53, making p53 a candidate for
mediating c-Myc–induced HLA-B downregulation [56].
However, transfection of c-Myc into p53-null cell lines still
resulted in suppression of the basal HLA-B promoter,
demonstrating that c-Myc and p53 repress the minimal
HLA-B promoter through independent mechanisms [56].
The crucial molecular step in ionizing radiation- induced
apoptosis by radiotherapy is the release of mitochondrial
cytochrome c into the cytosol [57]. The precise ways the
tumor suppressor protein p53, as well as the oncoprotein c-
Myc, as well as Ras and Raf, and Bcl -2 gene can influence
this process at different stages are still poorly understood
[57]. Indeed, the result of activation of an oncoprotein on
tumor radiosensitivity depends on its mechanism of action
and on the presence of other prooncogenic factors, because
complex interactions among many molecular factors deter-
mine the delicate balance between cell proliferation and cell
death. The ongoing identification and characterization of
these factors influencing this pathophysiologic scenario will
eventually make it possible to predict tumor radiosensitivity
and thereby improve cancer treatment [57].
c-Myc and Angiogenesis
The ability of neoplastic cells to recruit blood vessels is
crucial to their survival and growth in the host organism.
However, the evidence linking dominant oncogenes to the
angiogenic switch remains incomplete. Interestingly, the
oncoprotein c-Myc stimulates neovascularization in several
malignancies [7,8,55,56,58]. For example, angiogenesis
was identified as an early consequence of c-Myc over-
expression in two models of retroviral lymphomagenesis;
Avian leukosis virus induces bursal lymphoma in chickens
after proviral c-Myc gene integration, whereas the HB-1
retrovirus carries a v-Myc oncogene and also induces
metastatic lymphoma. Overexpression of c-Myc confers on
the conditioned media the ability to promote migration of
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adjacent endothelial cells in vitro and corneal neovasculari-
zation in vivo, and furthermore, mobilization of estrogen-
dependent c-Myc in vivo with the appropriate steroid
provokes neovascularization of cell implants [59]. These
data indicate that c-Myc is capable of triggering the
angiogenic switch in vivo, and that secondary events may
not be required for neovascularization of c-Myc–induced
tumors.
Indeed, ectopic c-Myc overexpression in the low Myc B
cell lines increased endothelial growth activity, indicating that
c-Myc induces secretion of angiogenic factors from B cells
[60]. These findings demonstrated that c-Myc overexpres-
sion in lymphocytes generates also an angiogenic pheno-
type in vitro as well as in vivo.
Overexpression of c-Myc causes downregulation of the
thrombospondin-1 ( tsp-1) gene, an important negative
modulator of tumor angiogenesis, and c-Myc in combina-
tion with Max can bind, albeit with low affinity, to an
E-box–like element in the tsp-1 promoter [61]. However,
the 2.7-kb DNA segment containing both this noncanonical
E-box and other promoter- like sequence does not
constitute a c-Myc–responsive element in a transient
expression system. Furthermore, c-Myc does not signifi-
cantly affect the rate of initiation or elongation of the tsp-1
mRNA. Thus, in this case c-Myc does not seem to act as
a canonical transcription factor. Instead, as demonstrated
by blocking de novo RNA synthesis, downregulation of the
tsp-1 gene by c-Myc occurs through increased mRNA
turnover. Thus, gene regulation by c-Myc may involve
mRNA destabilization.
Modulation of c-Myc may also partly account for the
mechanism of action of some antiangiogenic drugs. Endo-
statin is a potent endogenous angiogenesis inhibitor that
induces regression of tumors in mice. Neither an extrac-
ellular receptor for endostatin nor intracellular signals that
result in the regression of tumor vascular beds have been
identified. Endostatin, but not angiostatin, at concentrations
comparable to those used in in vivo animal studies, rapidly
downregulates many genes in exponentially growing endo-
thelial cells including c-Myc [62]. Suppression of both
apoptosis inhibitors and cell proliferation genes may have a
limited contribution to the antiangiogenesis process because
endostatin induces neither apoptosis nor growth inhibition
unless studied under reduced serum conditions. In contrast,
the antimigratory effect of endostatin was rapid and potent
even under serum-supplemented conditions. Endostatin
caused gene suppression and migration arrest exclusively
in endothelial cells, most profoundly in microvascular
endothelial cells. The c-Myc null fibroblasts obtained by
targeted homologous recombination showed an attenuated
migration rate compared with isogenic parental cells,
whereas the introduction of the c-Myc gene into endothelial
cells abrogated the antimigratory effect of endostatin [62].
Inhibition of E-box–driven transcription by overexpressing
Max or Mad suppressed endothelial migration. Thus, rapid
downregulation of genes by endostatin neither restores
proliferating endothelial cells to their resting states nor
induces apoptosis; rather, it potently inhibits endothelial cell
migration partly through suppression of c-Myc expression.
As described, in addition to angiogenesis, c-Myc may play
other roles in neoplasia such as positive or negative
signaling for apoptosis [7,8,47-49,50,51,55,56,63] and loss
of growth inhibition [7,8,64] that may affect vascular cell
signaling.
Conclusions
A growing bulk of evidence suggests that c-Myc may play a
dual pathogenic role in neoplasia and cardiovascular
diseases (Figure 1 ). Most of these studies carried in the
cardiovascular system did not provide a causal role of c-Myc
in the disease but these data are consistent with the
hypothesis that alterations of the c-Myc–dependent signal-
ing network are involved in the early pathogenesis of
common cardiovascular diseases. The c-Myc gene produ-
ces an oncogenic transcription factor that affects diverse
cellular processes involved in cell growth, cell proliferation,
apoptosis, and cellular metabolism. Complete removal of c-
Myc results in slowed cell growth and proliferation, suggest-
ing that although c-Myc is not required for cell proliferation, it
acts as an integrator and accelerator of cellular metabolism
and proliferation [65]. Down-regulation of c-Myc induced by
intervention with antioxidants [34,35,37] may induce rele-
vant effects in the arterial wall [66-68] and in neoplastic
tissues [34]. Similarly, the use of c-Myc antisense oligomers
may reduce vascular diseases. Microarray can identify c-
Myc–dependent target genes involved in cardiovascular
disorders [67,68]. Further intervention studies are neces-
sary to investigate the effects of tissue-specific block of c-
Myc during certain neoplastic and cardiovascular diseases.
To date, the PREVENT trial [26] provides a novel approach
Figure 1. Flow chart depicting the proposed sequela of events leading to the
dual role of c -Myc activation in neoplasia and cardiovascular diseases. C -
Myc is involved in several neoplasias as indicated. Restenosis through the
activation of the cell cycle progression proteins such as cyclin E and ornithine
decarboxylase, but it also increases transcription of proliferation genes such
as c -Fos and c -Jun. During atherogenesis there is activation of several c -
Myc–dependent transcription factors such as AP-1 ( activation protein 1 ),
E2F (elongation factor - 2 ) and AP-2 ( activation factor - 2 ). Cardiac hyper-
thropy stimulates the activity of phosphoinositol - 3 -phosphate kinase (PI3K )
and phospholipase C -gamma (PLC- ). Finally, myocardial ischemia–
reperfusion induces c -Myc–dependent activation of the transcription factor
NFB (nuclear factor kappa B ) whereas during angiogenesis there is a
concomitant activation of the thrombospondin - 1 factor ( tsp - 1 ).
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that reduced graft failure and c-Myc expression within
vessel.
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